Open House Pharmaceutical Rebate Agreements Lamivudine and Dolutegravir, ATC J05AR25

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 584 days left·Open·Supplies·Framework

Structured notice only

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamivudin und Dolutegravir, ATC J05AR25

45/100

Opportunity Score

Needs reviewLow complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

45 / 100

Complexity

20 / 100

Risk factors

The open-house model is not subject to procurement law. Legal recourse is through social courts, not procurement review...

No estimated value or volume commitments. The agreement may result in negligible revenue if the drug is not widely pres...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until May 2028
Entering into non-exclusive rebate agreements for lamivudine and dolutegravir (ATC J05AR25).
Contracts run from June 1, 2026 to May 31, 2028.

Show full summary

This is an open-house model for non-exclusive rebate agreements for the active ingredients lamivudine and dolutegravir (ATC J05AR25) by AOK Bayern. It is not a competitive procurement but a voluntary participation model. All eligible pharmaceutical companies can join. No estimated value provided. The contract period is June 1, 2026 to May 31, 2028, with contracts possible at any time until April 3, 2028. Monthly deadlines apply for start dates.

Risks

The open-house model is not subject to procurement law. Legal recourse is through social courts, not procurement review...

No estimated value or volume commitments. The agreement may result in negligible revenue if the drug is not widely pres...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

Must be a pharmaceutical company.

Administrative

Submit a signed and completed contract along with annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria specified; participation is open to all eligible companies.

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open House Pharmaceutical Rebate Agreements Lamivudine and Dolutegravir, ATC J05AR25

Non-exclusive rebate agreement for lamivudine and dolutegravir. All eligible pharmaceutical companies may join with identical terms. Monthly submission deadlines (3rd of month) for start on the 1st of next month. Final deadline for conclusion is April 3, 2028.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

May 2026 - May 2028

Procurement Details

Publication date: 14 Apr 2026
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 256387-2026

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3